Legend Biotech Corp (LEGN)vsVertex Pharmaceuticals Inc (VRTX)
LEGN
Legend Biotech Corp
$18.64
+0.59%
HEALTHCARE · Cap: $3.60B
VRTX
Vertex Pharmaceuticals Inc
$516.34
+0.26%
HEALTHCARE · Cap: $130.56B
Smart Verdict
WallStSmart Research — data-driven comparison
Vertex Pharmaceuticals Inc generates 890% more annual revenue ($12.59B vs $1.27B). VRTX leads profitability with a 35.0% profit margin vs -7.2%. VRTX earns a higher WallStSmart Score of 64/100 (C+).
LEGN
Hold42
out of 100
Grade: D
VRTX
Buy64
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Intrinsic value data unavailable for LEGN.
Margin of Safety
+46.3%
Fair Value
$960.82
Current Price
$516.34
$444.48 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 51.9% year-over-year
Conservative balance sheet, low leverage
Reasonable price relative to book value
Keeps 35 of every $100 in revenue as profit
Strong operational efficiency at 38.1%
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Every $100 of equity generates 22 in profit
Areas to Watch
0.0% earnings growth
Weak financial health signals
ROE of -25.9% — below average capital efficiency
Negative free cash flow — burning cash
Expensive relative to growth rate
Moderate valuation
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : LEGN
The strongest argument for LEGN centers on Revenue Growth, Debt/Equity, Price/Book. Revenue growth of 51.9% demonstrates continued momentum.
Bull Case : VRTX
The strongest argument for VRTX centers on Profit Margin, Operating Margin, Debt/Equity. Profitability is solid with margins at 35.0% and operating margin at 38.1%. Revenue growth of 12.5% demonstrates continued momentum.
Bear Case : LEGN
The primary concerns for LEGN are EPS Growth, Piotroski F-Score, Return on Equity.
Bear Case : VRTX
The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.
Key Dynamics to Monitor
LEGN profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.
LEGN carries more volatility with a beta of 0.40 — expect wider price swings.
LEGN is growing revenue faster at 51.9% — sustainability is the question.
VRTX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
VRTX scores higher overall (64/100 vs 42/100), backed by strong 35.0% margins and 12.5% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Legend Biotech Corp
HEALTHCARE · BIOTECHNOLOGY · USA
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, is dedicated to the discovery and development of new cell therapies for oncology and other indications in North America and internationally.
Vertex Pharmaceuticals Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?